Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor.
Yuqi YangNing JiChao-Yun CaiJing-Quan WangZi-Ning LeiQiu-Xu TengZhuo-Xun WuQingbin CuiYihang PanZhe-Sheng ChenPublished in: Cancer communications (London, England) (2020)
The findings in this study suggest that the combination of sitrvatinib and substrate antineoplastic drugs of ABCB1 could attenuate the MDR mediated by the overexpression of ABCB1.